Search Within

David Solit

Formats
  1. Meeting Abstract (391)
  2. Journal Article (366)
  3. Editorial (9)
  4. Book Section (4)
  5. Research Letter (4)
  6. Review (4)
  7. Correspondence (2)
  8. Guidelines (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (783)
  2. GSK Faculty (783)
  3. Genitourinary Oncology Service (783)
  4. Human Oncology and Pathogenesis Program (783)
  5. Solid Tumor Oncology Division (783)
  6. Department of Pathology and Laboratory Medicine (510)

More Groups

People
  1. Michael Berger (317)
  2. Hikmat Al-Ahmadie (186)
  3. Gopakumar Iyer (184)
  4. Neal Rosen (155)
  5. Nikolaus Schultz (150)
  6. Dean Bajorin (130)

More People

Years
  1. 2025 (17)
  2. 2024 (38)
  3. 2023 (39)
  4. 2022 (44)
  5. 2021 (47)
  6. 2020 (59)

More Years

Publications
  1. Journal of Clinical Oncology (163)
  2. Cancer Research (99)
  3. Clinical Cancer Research (77)
  4. Laboratory Investigation (42)
  5. Modern Pathology (37)
  6. Cancer Discovery (24)

More Publications

Publishers
  1. American Association for Cancer Research (219)
  2. American Society of Clinical Oncology (181)
  3. Nature Publishing Group (97)
  4. Nature Research (39)
  5. Elsevier Inc. (31)
  6. Oxford University Press (29)

More Publishers

Results (783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors
    Meeting Abstract

    Eiseman, J. L.; Guo, J.; Weinbaum, B.; Ramanathan, R. K.; Belani, C. P.; Solit, D. B.; Scher, H. I.; Ivy, S. P.; Zuhowski, E. G.; Egorin, M. J.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel
    Journal Article

    Solit, D. B.; She, Y.; Lobo, J.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Journal Article

    Morris, M. J.; Divgi, C. R.; Pandit-Taskar, N.; Batraki, M.; Warren, N.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Kelly, W. K.; Slovin, S.; more...
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Induction of complete regressions of oncogene-induced breast tumors in mice
    Conference Paper

    Benezra, R.; Henke, E.; Ciarrocchi, A.; Ruzinova, M.; Solit, D.; Rosen, N.; Nolan, D.; Mittal, V.; De Candia, P.
    Cold Spring Harbor Laboratory Press (2005)

    Fulltext@MSK | Save
  • The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
    Journal Article

    She, Qing Bai; Solit, David B.; Ye, Qing; O'reilly, Kathryn E; Lobo, Jose; Rosen, Neal
    Cancer Cell (2005)

    Fulltext@MSK | Save
  • Restoration of PTEN-expression in tumor cells causes them to depend on EGFR for suppression
    Meeting Abstract

    She, Q.; Moasser, M. M.; Ye, Q.; O'reilly, K.; Solit, D.; Rosen, N.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Cyclin D expression and G1 progression are dependent on MEK-MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras and Raf
    Meeting Abstract

    Pratilas, C. A.; Grbovic, O.; Basso, A. D.; Sawai, A.; Chapman, P.; Rosen, N.; Solit, D. B.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Activated, mutated B-raf protein kinase requires the HSP90 chaperone for folding and stability and is degraded in response to HSP90 inhibitors
    Meeting Abstract

    Grbovic, O. M.; Basso, A. D.; Friedlander, P.; Houghton, A.; Solit, D. B.; Rosen, N.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Combinatorial targeting of oncogenesis via a novel rationally designed Hsp90 inhibitor
    Meeting Abstract

    Chiosis, G.; Solit, D.; Vilenchik, M.; Rosen, N.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates the G(2)/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison
    Meeting Abstract

    Tse, A. N.; Solit, D.; Rosen, N.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save